605 related articles for article (PubMed ID: 22987083)
1. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
[TBL] [Abstract][Full Text] [Related]
2. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y
Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935
[TBL] [Abstract][Full Text] [Related]
3. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
[TBL] [Abstract][Full Text] [Related]
4. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.
Lawrie TA; Bryant A; Cameron A; Gray E; Morrison J
Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD006910. PubMed ID: 23835762
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
[TBL] [Abstract][Full Text] [Related]
6. A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.
Nakanishi T; Aoki D; Watanabe Y; Ando Y; Tomotsugu N; Sato Y; Saito T
Jpn J Clin Oncol; 2015 May; 45(5):422-6. PubMed ID: 25670764
[TBL] [Abstract][Full Text] [Related]
7. Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group.
Katsumata N; Fujiwara Y; Kamura T; Nakanishi T; Hatae M; Aoki D; Tanaka K; Tsuda H; Kamiura S; Takehara K; Sugiyama T; Kigawa J; Fujiwara K; Ochiai K; Ishida R; Inagaki M; Noda K
Jpn J Clin Oncol; 2008 Nov; 38(11):777-85. PubMed ID: 18927230
[TBL] [Abstract][Full Text] [Related]
8. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
Monk BJ; Herzog TJ; Kaye SB; Krasner CN; Vermorken JB; Muggia FM; Pujade-Lauraine E; Park YC; Parekh TV; Poveda AM
Eur J Cancer; 2012 Oct; 48(15):2361-8. PubMed ID: 22541893
[TBL] [Abstract][Full Text] [Related]
9. Retrospective study comparing irinotecan and pegylated liposomal doxorubicin in treatment of recurrent platinum-refractory/resistant epithelial ovarian cancer.
Nomura H; Tsuda H; Kataoka F; Chiyoda T; Yamagami W; Tominaga E; Susumu N; Aoki D
Eur J Gynaecol Oncol; 2012; 33(1):86-9. PubMed ID: 22439412
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
[TBL] [Abstract][Full Text] [Related]
11. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Pujade-Lauraine E; Fujiwara K; Ledermann JA; Oza AM; Kristeleit R; Ray-Coquard IL; Richardson GE; Sessa C; Yonemori K; Banerjee S; Leary A; Tinker AV; Jung KH; Madry R; Park SY; Anderson CK; Zohren F; Stewart RA; Wei C; Dychter SS; Monk BJ
Lancet Oncol; 2021 Jul; 22(7):1034-1046. PubMed ID: 34143970
[TBL] [Abstract][Full Text] [Related]
12. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
Banerjee S; Oza AM; Birrer MJ; Hamilton EP; Hasan J; Leary A; Moore KN; Mackowiak-Matejczyk B; Pikiel J; Ray-Coquard I; Trask P; Lin K; Schuth E; Vaze A; Choi Y; Marsters JC; Maslyar DJ; Lemahieu V; Wang Y; Humke EW; Liu JF
Ann Oncol; 2018 Apr; 29(4):917-923. PubMed ID: 29401246
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study.
Thaker PH; Brady WE; Lankes HA; Odunsi K; Bradley WH; Moore KN; Muller CY; Anwer K; Schilder RJ; Alvarez RD; Fracasso PM
Gynecol Oncol; 2017 Nov; 147(2):283-290. PubMed ID: 28802766
[TBL] [Abstract][Full Text] [Related]
14. The Safety of Pegylated Liposomal Doxorubicin Plus Irinotecan in Recurrent Ovarian Cancer Patients: A Phase I Trial.
Miyahara D; Ueda T; Katsuda T; Maehara M; Fukagawa S; Miyata K; Nam SO; Kondo H; Miyamoto S
Anticancer Res; 2015 Aug; 35(8):4521-5. PubMed ID: 26168496
[TBL] [Abstract][Full Text] [Related]
15. Clinical trials of palliative chemotherapy in platinum-resistant or -refractory ovarian cancer: time to think differently?
Friedlander ML; Stockler MR; Butow P; King MT; McAlpine J; Tinker A; Ledermann JA
J Clin Oncol; 2013 Jun; 31(18):2362. PubMed ID: 23669225
[No Abstract] [Full Text] [Related]
16. A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer.
Rustin G; Vergote I; Micha JP; Duska LR; Reed N; Bendell J; Spitz D; Dark G; Hoch U; Tagliaferri M; Hannah AL; Garcia AA
Gynecol Oncol; 2017 Nov; 147(2):276-282. PubMed ID: 28935273
[TBL] [Abstract][Full Text] [Related]
17. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
Monk BJ; Herzog TJ; Wang G; Triantos S; Maul S; Knoblauch R; McGowan T; Shalaby WSW; Coleman RL
Gynecol Oncol; 2020 Mar; 156(3):535-544. PubMed ID: 31924332
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):369-72. PubMed ID: 10985896
[TBL] [Abstract][Full Text] [Related]
19. Outcomes with single agent LIPO-DOX in platinum-resistant ovarian and fallopian tube cancers and primary peritoneal adenocarcinoma - Chiang Mai University Hospital experience.
Suprasert P; Manopunya M; Cheewakriangkrai C
Asian Pac J Cancer Prev; 2014; 15(3):1145-8. PubMed ID: 24606432
[TBL] [Abstract][Full Text] [Related]
20. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
